A LISTENING COMPANY
"Speaking RA: Rheumatoid Arthritis Patient Lexicon Guide"
More than physicians, nurses, or payers, hospital pharmacists are closest to issues related to biosimilars and can provide a broad perspective on this subject. In February 2018, inVibe fielded an open-ended, eight-question survey to Hospital Pharmacy Directors and Associate Directors responsible for making formulary recommendations, including purchasing, acquiring, and dispensing biosimilars.
The study objective was to understand how hospital pharmacists currently perceive and utilize biosimilars in comparison to the originators’ corresponding biological products.
With the possible exception of breast cancer, biomarker testing is more established in non-small cell lung cancer (NSCLC) than in other oncology indications. If you believe that NSCLC biomarker testing is fully standardized, you would be wrong. Our survey respondents taught us that we are only at the end of the beginning of standardization of NSCLC biomarker testing.
Explore the following topics:
"Rheumatoid Arthritis Patient Lexicon Guide"
This free whitepaper demonstrates how new technologies have reduced the barriers to gathering rich qualitative insights, and why this is important to decision-makers.
On a tight timeline? Call us.(949) 438-4836
Or send an email to our team:
inVibe OC (HQ)2900 Bristol St.
Building D, Suite 201Costa Mesa, CA 92626
1100 Ludlow StreetPhiladelphia, PA 19107
Complete the form below and we'll get back to you within 24 hours.
inVibe Labs, LLC
2900 Bristol St., Suite D201
Costa Mesa, CA 92626
Tel (949) 438-4836